COVID
345
13
16
175
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
32 trials with published results (9%)
Research Maturity
175 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.9%
34 terminated out of 345 trials
83.7%
-2.8% vs benchmark
10%
33 trials in Phase 3/4
18%
32 of 175 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 175 completed trials
Clinical Trials (345)
Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic
Cohort Study of Intraoperative Lung Protective Ventilation Trends in a Large Canadian Health Authority
Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection
Vitamin D Levels in SARS-CoV-2: Do Current Adequacy Thresholds Reflect Clinical Risk? Insights From a Large Turkish Cohort
Risk of Air Contamination During Visceral Surgery in COVID19 Patients
Intermediate IND Severe Illness COVID-19 CP
SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test
Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19
Covid-19 Data Analyses in Brazil
Myeloproliferative Neoplasms (MPN) and COVID-19
Nebulised Rt-PA for ARDS Due to COVID-19
COVID-19 Biorepository
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)